The firm invests in early and later stage companies in the biotechnology sector, with a focus on discovering and developing human therapeutics in areas such as oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. They also invest in discovery research and technology, including drug discovery collaborations, diagnostics, biomarkers, and novel antibody platforms. Amgen Ventures typically invests between $2 million and $3 million per transaction, with a maximum investment of $10 million per company. They prefer to have an ownership stake of less than 15% in their portfolio companies. Founded in 2004, Amgen Ventures is based in San Francisco, California, with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.